Fig. 4.

IL-10 signaling in CD4⁺ T cells is critical in controlling diabetes development. (A) Individual glycemia values of anti-CD3–treated recent-onset diabetic NOD mice (Left) and CD4–DN–IL-10R NOD mice (Right). Blood glucose concentrations were monitored until 12 wk posttreatment initiation. (B) Percentages of nondiabetic mice in NOD (n = 15) and CD4–DN–IL-10R NOD (n = 12) mice after anti-CD3 treatment. *P = 0.03. Statistical significance between groups was calculated using a log-rank (Mantel–Cox) test. (C) IL-10R expression was measured by flow cytometry. Cells were gated on CD4⁺CD25⁻ T cells, and Th1 (CD4⁺IFNγ⁺) cells were isolated from the spleen of a prediabetic and diabetic mouse. Results are representative of at least two independent experiments.